London-based Basecamp Research, which says its BaseFold model outperforms AlphaFold 2 at predicting proteins, raised a $60M Series B, for $85M in total funding
Context & Ripple Effects
London had already produced well-funded AI drug-discovery efforts, including BenevolentAI’s $115M funding round, while Cradle’s $24M Series A showed investor interest in protein engineering specifically. Basecamp’s financing adds a structure-prediction contender to that local and specialist ecosystem.
The significance rests on BaseFold’s stated comparison with AlphaFold 2: a large round behind a model-level performance claim makes independent validation and practical adoption the next meaningful tests, rather than funding alone.
First-order effects
- Basecamp gains $60M of new capital, taking disclosed funding to $85M and giving the company more resources to develop and commercialize BaseFold.
- The company’s claim of stronger protein-structure predictions than AlphaFold 2 puts its model’s benchmarks and real-world utility under closer scrutiny from prospective users and researchers.
Second-order effects
- Other protein-AI developers, including protein-design platforms such as Cradle, face greater pressure to show where their models outperform alternatives—whether on prediction quality, engineering workflows, or usability.
- The round reinforces investor attention on specialized biomolecular models; later coverage of Boltz’s seed financing for open biomolecular AI models illustrates that competition is extending across both proprietary and open-model approaches.
Third-order effects
- If performance claims translate into reproducible results, protein AI is likely to segment into competing layers—structure prediction, protein design, and downstream drug-discovery workflows—rather than remaining a single broad “AI for biology” category.
- Capital will increasingly favor teams that can pair model claims with credible evaluation and usable research workflows, although the corpus does not establish which approach will prove durable.
The trend: This is one data point in the maturation of AI-for-biology from broad drug-discovery platforms toward capital-intensive, specialized models for protein research.